O agonista oral do receptor GLP-1 da Eli Lilly, Foundayo (ozaglitazona), demonstrou controle superior da hemoglobina glicada A1C e perda de peso em três estudos clínicos fundamentais para o tratamento do diabetes tipo 2.
Indianápolis, 8 de junho de 2026 /PRNewswire/ -- A Eli Lilly and Company (NYSE: LLY), fabricante…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
常見問題
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
